Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lou Gehrig's Disease Clear all
Recruiting Not applicable Interventional

Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study

NCT06649955
View directory record Official record
Conditions
ALS - Amyotrophic Lateral Sclerosis
Interventions
Multi-site direct current stimulation (DCS)
Device
Lead sponsor
PathMaker Neurosystems Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 1Phase 2 Interventional

Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis

NCT00956488
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Lou Gehrig's Disease
Interventions
Treadmill Exercise
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
25 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Jul 24, 2026, 1:07 AM EDT
No Longer Available No phase listed Expanded access

Intermediate-Sized Expanded Access Study

NCT05597436
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Trehalose
Drug
Lead sponsor
Seelos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
21
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Jul 24, 2026, 1:07 AM EDT
Active, not recruiting Phase 2 Interventional

T-regulatory Cells in ALS

NCT04055623
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections, Monthly placebo infusions + 3 times per week placebo injections
Biological · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262

NCT05740813
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
ABBV-CLS-7262 Dose 1, ABBV-CLS-7262 Dose 2, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 24, 2026, 1:07 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Digital Speech Markers for Monitoring ALS in Spanish Speakers

NCT07341334
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, ALS
Interventions
Not listed
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen G DNL343

NCT05842941
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
DNL343, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)

NCT00931944
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
KNS-760704
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
21 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
19
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

NCT01257581
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
creatine, tamoxifen
Drug
Lead sponsor
Nazem Atassi
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Kansas City, Kansas • Boston, Massachusetts • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Jul 24, 2026, 1:07 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00420719
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Intramuscular diaphragm electrodes
Device
Lead sponsor
Synapse Biomedical
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
7
States / cities
San Francisco, California • Stanford, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2009 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen C CNM-Au8

NCT04414345
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CNM-Au8, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Jul 24, 2026, 1:07 AM EDT
Recruiting No phase listed Observational

Analysis of Human ALS Tissues and Registry of ALS Patients

NCT05067179
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Tocilizumab in ALS Subjects

NCT02469896
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, Motor Neuron Disease
Interventions
Tocilizumab, Placebo
Drug · Other
Lead sponsor
Barrow Neurological Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Phoenix, Arizona • Kansas City, Kansas • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 4 Interventional Results available

Mexiletine for the Treatment of Muscle Cramps in ALS

NCT01811355
View directory record Official record
Conditions
Muscle Cramps in Amyotrophic Lateral Sclerosis
Interventions
Mexiletine, Placebo
Drug
Lead sponsor
Bjorn Oskarsson, MD
Other
Eligibility
21 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Chester, California • La Jolla, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2017 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional

Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00072709
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
TCH346
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
21 Years to 80 Years
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Jul 24, 2026, 1:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetics of Familial and Sporadic ALS

NCT00821132
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Familial Amyotrophic Lateral Sclerosis, ALS With Frontotemporal Dementia (ALS/FTD), Lou Gehrig's Disease, Motor Neuron Disease (MND), Primary Lateral Sclerosis (PLS), Sporadic ALS (SALS)
Interventions
Genetic study of ALS families
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
13,521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2Phase 3 Interventional

Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00125203
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Sialorrhea
Interventions
Botulinum toxin type B (Myobloc), Injection of salivary glands
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
21 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Kansas City, Kansas • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Jul 24, 2026, 1:07 AM EDT
Not listed No phase listed Observational

Rehabilitation in SOD1 ALS Treated With Tofersen

NCT05725759
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Lou Gehrig Disease, Familial Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Motor Neuron Disease, Familial
Interventions
Rehabilitation
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Dexpramipexole in ALS

NCT01281189
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Placebo
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
43
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Jul 24, 2026, 1:07 AM EDT
Recruiting Phase 2 Interventional

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

NCT07142291
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo, Riluzole (100 mg)
Drug
Lead sponsor
PhenoNet, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Not applicable Interventional Results available

Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation

NCT00116558
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Early NIPPV, Standard NIPPV
Device
Lead sponsor
Edward Kasaraskis
Other
Eligibility
18 Years to 80 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
12
States / cities
Denver, Colorado • Miami, Florida • Lexington, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Jul 24, 2026, 1:07 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders

NCT01459302
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, PLS, Motor Neuron Disease, Lou Gehrigs Disease, Familial Disease, Amyotrophic Lateral Sclerosis, Sporadic, Muscular Dystrophy, Miyoshi Myopathy, Amyotrophic Lateral Sclerosis With Dementia
Interventions
Not listed
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2Phase 3 Interventional

Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement

NCT00386464
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
noninvasive positive pressure ventilation
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2007 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 1 Interventional

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

NCT03520517
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease, Lou-Gehrigs Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
BHV-0223
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Lincoln, Nebraska • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Jul 24, 2026, 1:07 AM EDT